The latest call
FetchingTwist Bioscience Corporation reported on 2026年11月12日. We are fetching the call transcript; its summary follows once the transcript is in.
US$111.60-2.3%11月13日 收盘
The latest quarter (ended 2026年9月30日) is from Twist Bioscience’s earnings press release of 2026年11月12日. It will be replaced by the official annual report (10-K) once Twist Bioscience files it.
公司指引:2027 财年第 1 季度营收 US$130M 至 US$132M — 同比增长 26.3%
Just reported
From Twist Bioscience Corporation's results release of 2026年11月12日. These are the company's first figures; its 10-Q or 10-K replaces them when filed.
Actual
US$126.6M
+28% y/y
+7.0% q/q
Guided
—
No guide given
Actual
-US$24.4M
Guided
—
No guide given
Q1 FY2027
| 指标 | 截至该日的 3 个月2026年9月30日 | 截至该日的 3 个月2025年9月30日 | 变动 |
|---|---|---|---|
| 营业收入合计 | US$126.6M | US$99M | +27.91% |
| 利润 | -US$20.6M | -US$27.1M | +24.01% |
这些是单季度数字,不是滚动一年——本站其他地方的数字覆盖十二个月,会大得多。季节性业务在两者之间摆动很大:ServiceNow 在十二月季度赚 20 亿美元自由现金流,在六月季度只有 5 亿。
对比对象是去年同一季度,而不是分析师预测。要说“超预期”或“不及预期”需要一致预期数据,那是我们没有的授权数据——而搞错它比不提更糟。
Twist Bioscience Corporation reported on 2026年11月12日. We are fetching the call transcript; its summary follows once the transcript is in.
“Fiscal 2026 demonstrated what Twist can deliver: strong top line revenue growth, expanded gross margin and positive adjusted EBITDA in the fourth quarter, all while continuing to broaden our capabilities and strengthen our balance sheet,”
逐字引自公告,且只在文件将其归于具名人士时才展示。
公告在开盘前或收盘后发布,因此区间从公告日前一个交易日的收盘价到公告日之后那个交易日的收盘价——无论哪种情况,反应都包含在内。
Twist Bioscience, our customizable solutions across the biological continuum raise the bar in diagnostics, therapeutics, industrial, agriculture and research markets. We drive innovation with confidence, without compromise. Whether delivering oligos, genes, proteins, libraries, characterization data, antibody discovery solutions, or NGS workflow tools, our scientific expertise and exceptional customer experience help navigate complex challenges, all with precision and at the scale and speed customers require. By enhancing R&D efficiency at every turn, we give scientists more shots on goal – more experiments, more iterations, more chances for remarkable discoveries. Together, we stand with customers in the relentless pursuit of progress, backed by enterprise reliability, to shape a healthier and more sustainable future for all.
公司自己的描述,取自公告末尾。
The quote, the company description and the latest quarter come from Twist Bioscience’s earnings press release (an Item 2.02 8-K) filed 2026年11月12日. Earlier quarters come from its quarterly and annual reports, and the latest will be replaced once the official report is filed. 在 EDGAR 上阅读公告 股价已按拆股和分红复权。
Full year 2027
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.